HF Advisory Group LLC Has $1.49 Million Position in Sanofi (NASDAQ:SNY)

HF Advisory Group LLC boosted its position in Sanofi (NASDAQ:SNY) by 7.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,812 shares of the company’s stock after acquiring an additional 2,049 shares during the quarter. HF Advisory Group LLC’s holdings in Sanofi were worth $1,486,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SNY. Victory Capital Management Inc. boosted its stake in Sanofi by 11.9% in the second quarter. Victory Capital Management Inc. now owns 6,793 shares of the company’s stock valued at $330,000 after buying an additional 722 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Sanofi by 8.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 141,159 shares of the company’s stock worth $6,849,000 after acquiring an additional 10,941 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Sanofi by 0.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 318,760 shares of the company’s stock valued at $15,466,000 after purchasing an additional 1,238 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of Sanofi by 2,735.8% during the 2nd quarter. Hsbc Holdings PLC now owns 279,981 shares of the company’s stock valued at $13,661,000 after purchasing an additional 270,108 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its position in Sanofi by 33.6% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 16,737 shares of the company’s stock worth $812,000 after purchasing an additional 4,207 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

SNY opened at $50.74 on Friday. The firm has a market capitalization of $128.77 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.17 and a beta of 0.57. The company’s 50 day moving average price is $48.46 and its two-hundred day moving average price is $52.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.55 earnings per share. As a group, research analysts predict that Sanofi will post 3.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.